Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Gilead Sciences, Inc. and its officers or directors [1] Group 1: Company Developments - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns related to decreases in CD4+ T-cell and absolute lymphocyte counts [3] - Following the FDA announcement, Gilead's stock price decreased by $2.91, or 2.58%, closing at $110.09 per share on the same day [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [3] - Following the announcement of the delay, PetMed's stock price dropped by $0.47 per share, representing an 11.22% decline, closing at $3.72 per share on June 11, 2025 [3] Group 2: Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of fighting for victims of securities fraud and corporate misconduct [4]

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Neogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 4, 20 ...

Core Viewpoint - UroGen Pharma Ltd. is under investigation for potential securities fraud and unlawful business practices following negative FDA feedback on its bladder cancer drug UGN-102 [1][3]. Group 1: FDA Review and Drug Approval - The FDA's briefing document indicated that UroGen's Envision trial lacked a concurrent control arm, making the interpretation of primary endpoints challenging [3]. - The FDA recommended a randomized trial design multiple times to address concerns regarding the trial's results [3]. - On May 21, 2025, the Oncologic Drugs Advisory Committee voted against the NDA for UGN-102, citing an unfavorable benefit-risk profile for patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer [4]. Group 2: Stock Price Impact - Following the FDA's briefing document release on May 16, 2025, UroGen's stock price dropped by $2.54, or 25.79%, closing at $7.31 per share [4]. - After the advisory committee's negative vote on May 21, 2025, UroGen's stock price fell by $3.37, or 44.7%, closing at $4.17 per share [4].

Core Viewpoint - Dyne Therapeutics is facing an investigation regarding potential securities fraud and unlawful business practices following a delay in FDA approval for its experimental therapy DYNE-101 for myotonic dystrophy type 1 [1][3]. Group 1: Company Developments - On June 17, 2025, Dyne Therapeutics announced a delay in filing for FDA approval of DYNE-101, which is intended for treating myotonic dystrophy type 1 [3]. - The company revised its protocol for the Phase 1/2 global ACHIEVE trial after a Type C meeting with the FDA, with the new enrollment goal set for the fourth quarter of 2025 and a potential data readout in mid-2026 [3]. - The previous timeline aimed for enrollment completion in mid-2025 and regulatory submission in the first half of 2026, indicating a significant shift in the project timeline [3]. Group 2: Market Reaction - Following the announcement of the delay, Dyne's stock price dropped by $2.96 per share, or 21.42%, closing at $10.86 per share on June 17, 2025 [4].

Core Viewpoint - Designer Brands Inc. is under investigation for potential securities fraud and unlawful business practices following a significant drop in stock price after the withdrawal of its 2025 guidance due to a challenging macro environment and consumer sentiment [1][2]. Financial Performance - On June 10, 2025, Designer Brands reported a soft start to 2025 and announced the withdrawal of its 2025 guidance, attributing this decision to an unpredictable macro environment and deteriorating consumer sentiment [2]. - The company's stock price fell by $0.68 per share, or 18.23%, closing at $3.05 per share on the same day [2]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors of Designer Brands regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Globus Medical reported financial results for Q1 2025, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, which was $27.78 million below expectations and represented a 1.4% year-over-year decline [3] - Following the disappointing financial results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3] Financial Performance - Non-GAAP earnings per share for Q1 2025 were reported at $0.68, missing estimates by $0.06 [3] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and showing a 1.4% decline compared to the previous year [3] - The decline in performance was attributed to softer deal closures, supply chain disruptions, and timing issues with international distributor orders [3] Stock Market Reaction - The stock price of Globus Medical experienced a significant drop of $16.64 per share, equating to a 22.96% decrease [3] - The closing price after the drop was $55.82 per share on May 9, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Summit Therapeutics Inc. and its officers or directors, following disappointing clinical trial results that negatively impacted the company's stock price [1][2]. Group 1: Clinical Trial Results - On May 30, 2025, Summit announced topline results from the Phase III clinical trial, HARMONi, evaluating ivonescimab, which showed that patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die compared to those receiving chemotherapy alone [2]. - Despite the positive progression-free survival results, the drug did not demonstrate a statistically significant difference in overall survival, which measures the duration patients live before dying from any cause [2]. Group 2: Stock Price Impact - Following the announcement of the clinical trial results, Summit's stock price fell by $7.99 per share, representing a 30.5% decline, closing at $18.22 per share on May 30, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is representing investors in investigating claims against Summit Therapeutics for potential securities fraud [1][4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Zeo Energy Corp and its officers or directors [1] Group 1: Company Compliance Issues - On May 29, 2025, Zeo announced it received a notice from Nasdaq regarding non-compliance with periodic filing requirements due to the failure to file its Quarterly Report on Form 10-Q by the due date of May 15, 2025 [2] - Following this announcement, Zeo's stock price decreased by $0.34 per share, representing a decline of 9.91%, closing at $3.09 per share on May 30, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Summit Therapeutics Inc. and its officers or directors following disappointing clinical trial results for its drug ivonescimab [1][3]. Group 1: Company Overview - Summit Therapeutics Inc. is a publicly traded company on NASDAQ under the ticker SMMT [1]. - The company recently announced topline results from its Phase III clinical trial, HARMONi, evaluating ivonescimab [3]. Group 2: Clinical Trial Results - The Phase III trial indicated that patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die compared to those receiving chemotherapy alone [3]. - However, the drug did not show a statistically significant difference in overall survival, which measures the duration patients live before dying from any cause [3]. Group 3: Market Reaction - Following the announcement of the clinical trial results, Summit's stock price dropped by $7.99 per share, representing a 30.5% decline, closing at $18.22 per share on May 30, 2025 [4].